CannaPharmaRx Inc
OTC:CPMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CannaPharmaRx Inc
Cost of Revenue
CannaPharmaRx Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CannaPharmaRx Inc
OTC:CPMD
|
Cost of Revenue
-$1.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cost of Revenue
-$3.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cost of Revenue
-CA$204.4m
|
CAGR 3-Years
30%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-27%
|
|
|
Cronos Group Inc
TSX:CRON
|
Cost of Revenue
-$83.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-90%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cost of Revenue
-CA$242.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-90%
|
|
CannaPharmaRx Inc
Glance View
CannaPharmaRx, Inc. engages in the research and manufacture of cannabinoid-based pharmaceuticals. The company is headquartered in Calgary, Alberta and currently employs 4 full-time employees. The principal activity of the Company is to negotiate, acquire and develop various cannabis cultivation projects throughout Canada. The firm's activities is centered around projects, such as the Great Northern Project, and the acquisition of Ramon Road Production Campus LLC. The firm is focused on producing wholesale cannabis and hemp for the medical market.
See Also
What is CannaPharmaRx Inc's Cost of Revenue?
Cost of Revenue
-1.8m
USD
Based on the financial report for Dec 31, 2025, CannaPharmaRx Inc's Cost of Revenue amounts to -1.8m USD.
What is CannaPharmaRx Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
6%
Over the last year, the Cost of Revenue growth was 6%.
